Skip to main content
Ocumension Therapeutics logo

Ocumension Therapeutics — Investor Relations & Filings

Ticker · 1477 ISIN · KYG674111011 LEI · 5493000USURI3SIL4Z85 HKEX Manufacturing
Open in API
Filings indexed 460 across all filing types
Latest filing 2022-04-26 AGM Information
Country KY Cayman Islands
Listing HKEX 1477

About Ocumension Therapeutics

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company dedicated to the research, development, and commercialization of first-in-class or best-in-class therapeutics. The company focuses on providing comprehensive treatment solutions for Chinese patients suffering from ocular diseases. Ocumension has established a complete ophthalmic drug product line, currently holding 20 drug assets covering both anterior and posterior segments of the eye. Its portfolio addresses major conditions such as chronic non-infectious uveitis, infective and allergic conjunctivitis, and diabetic macular edema. The company employs a strategy combining continuous scientific innovation, independent R&D, and strategic alliances to sustain the supply of innovative products across the ophthalmology field.

Recent filings

Filing Released Lang Actions
PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES&#x3b; PROPOSED RE-ELECTION OF RETIRING DIRECTORS&#x3b; PROPOSED RE-APPOINTMENT OF AUDITOR&#x3b; AND NOTICE OF ANNUAL GENERAL
AGM Information Classification · 95% confidence The document is a circular from the board of Ocumension Therapeutics dated April 27, 2022, containing detailed information about the upcoming Annual General Meeting (AGM) scheduled for June 24, 2022. It includes proposals for granting general mandates to issue and repurchase shares, re-election of retiring directors, re-appointment of auditor, and the notice of the AGM itself. The document contains a letter from the board, definitions, detailed explanations of proposals, and the notice of the AGM. It is not a transcript, earnings release, or financial report but rather a comprehensive circular related to the AGM, including proxy forms and voting instructions. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM. The document is lengthy (15,000 characters) and contains substantive content, not just an announcement or notice, so it is not an RPA or RNS. Therefore, the correct classification is AGM-R with high confidence.
2022-04-26 English
2021 Environmental, Social and Governance Report
Environmental & Social Information Classification · 100% confidence The document is titled '2021 Environmental Social and Governance Report' and contains detailed information about the company's ESG strategies, governance, stakeholder communication, and sustainability practices. It references the ESG Reporting Guide and covers environmental and social performance indicators for the year 2021. The content is focused on ESG matters rather than financial results or corporate governance changes. This matches the description of an Environmental & Social Information report (ESG report). The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement. Therefore, the appropriate classification is 'SR' for Environmental & Social Information.
2022-04-26 English
2021 Annual Report
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2021 年度報告' and contains detailed sections typical of an annual report, including Chairman's Statement, Financial Summary, Management Discussion and Analysis, Profiles of Directors and Senior Management, Corporate Governance Report, Report of Directors, Independent Auditor's Report, and full consolidated financial statements with notes. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of comprehensive financial data and detailed corporate information confirms this is the official yearly report covering company activity and full financial performance for the year 2021. FY 2021
2022-04-26 English
List of Directors and their Role and Function
Board/Management Information Classification · 95% confidence The document lists the members of the board of directors and their roles, including committee memberships. It does not contain financial data, earnings, or report content. It is an announcement related to the company's board structure and management roles. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on board composition, confirming this classification.
2022-04-08 English
APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF BOARD COMMITTEES
Board/Management Information Classification · 100% confidence The document is an announcement from Ocumension Therapeutics regarding the appointment of an independent non-executive director and changes in board committees. It details the biography, appointment terms, and compliance with listing rules. There is no financial data, no report attached or referenced as being published, and no mention of earnings, audit, or other financial reports. The content clearly relates to changes in the company's board of directors and governance structure. Therefore, it fits the category of Board/Management Information (MANG). The document length is moderate and contains detailed information about the director appointment, not just a brief notice, confirming it is a full announcement rather than a mere regulatory filing or report publication announcement.
2022-04-08 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 March 2022
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly return on movements in securities, specifically focusing on share capital, issued shares, share options, warrants, and other share-related movements for the month ended 31 March 2022. It is addressed to the Hong Kong Exchanges and Clearing Limited and includes confirmations related to compliance with listing rules and legal requirements. The document does not contain financial statements or management discussion but is a regulatory submission reporting share capital and share issuance activities. This type of document aligns with announcements related to share capital changes and share issuance rather than a full financial report or earnings release. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA).
2022-04-06 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.